Macular Society: Treatment trial for Stargardt diseases reaches the UK

12 February 2018
Source: Macular Society

Macular Society Logo

Researchers in the south of England will become the first in the UK to trial a new drug that could prevent sight loss caused by Stargardt disease, a currently untreatable condition.

Stargardt disease, also known as Stargardt macular dystrophy, affects the area of the retina called the macula and causes a reduction in central vision.

It is the most common form of juvenile macular degeneration and affects around one in 10,000 children who suffer a gradual decline in vision which leads to blindness in adulthood.

Professor Andrew Lotery, from University Hospital Southampton NHS Foundation Trust, is to lead the UK’s team in a £5 million study of the drug remofuscin with colleagues in the Netherlands, Italy, Germany and Norway.

Speaking about the new trial, Professor Lotery said: “There is no approved treatment available for Stargardt’s, so we are very excited about the opportunity to test remofuscin and offer these patients the hope that we may be able to stop the progression of the condition.”

Full story on the Macular Society Website

Related Posts

  • Macular Society Awards for Excellence

    27 March 2017

    Nominations for the Macular Society annual Awards for Excellence are now open. This year, along with their usual categories, they are introducing a new category…

  • Macular Society Launch New Website

    14 January 2016

    The Macular Society is the national charity for anyone affected by central vision loss. With over 21,000 members we are the biggest membership group in…

  • Macular Disease Society Professionals Survey

    8 December 2012

    The Macular Disease Society is a national charity dedicated to the support of people with all forms of macular disease, the most common being age-related…